1的影响 佐匹克隆治疗阻塞性睡眠呼吸暂停的严重程度和症状:一项随机对照试验。

PubMed ID
发表日期 2018年07月

原始出处 欧洲呼吸杂志
The European respiratory journal
作者 Carter  Sophie G  Carberry  Jayne C  Cho  Garry  Fisher  Lauren P  Rollo  Charlotte M  Stevens  David J  D'Rozario  Angela L  McKenzie  David K  Grunstein  Ronald R  Eckert  Danny J 

文献标题 1的影响 佐匹克隆治疗阻塞性睡眠呼吸暂停的严重程度和症状:一项随机对照试验。
Effect of 1 month of zopiclone on obstructive sleep apnoea severity and symptoms: a randomised controlled trial.

文献摘要

出于安全考虑,禁止在阻塞性睡眠呼吸暂停(OSA)中使用催眠药。最近的研究表明,根据病理生理学的不同,单晚使用催眠药会使某些患者的低氧血症恶化,而另一些患者则会降低OSA的严重程度。然而,缺乏更长的临床试验数据。本研究旨在确定1 佐匹克隆治疗一个月对无严重夜间低氧血症的中低呼吸觉醒阈值患者OSA严重程度、嗜睡和警觉性的影响。69名参与者用会厌导管完成了一晚的生理学筛查,以量化觉醒阈值。30名合格患者(呼吸暂停低通气指数(AHI)22±11 事件·h-1),然后完成标准的实验室多导睡眠图(基线),在接受夜间佐匹克隆(7.5 mg)或安慰剂进行为期1个月的双盲随机平行试验(ANZCTR标识符ANZCTRN12613001006729)。佐匹克隆组与安慰剂组之间从基线检查到第30晚的AHI变化没有差异(-5.9±10.2 vs-2.4±5.5 事件·h-1;p=0.24)。同样,低氧血症、次日嗜睡和驾驶模拟器的表现也没有差异。1个月的佐匹克隆不会加重OSA的严重程度、嗜睡或警觉性,这些患者没有严重的夜间低氧血症。作为第一项评估安眠药对OSA严重程度和嗜睡影响的研究,这些发现为OSA病理生理学提供了重要的安全数据和见解。


Hypnotic use in obstructive sleep apnoea (OSA) is contraindicated due to safety concerns. Recent studies indicate that single-night hypnotic use worsens hypoxaemia in some and reduces OSA severity in others depending on differences in pathophysiology. However, longer clinical trial data are lacking. This study aimed to determine the effects of 1 month of zopiclone on OSA severity, sleepiness and alertness in patients with low-moderate respiratory arousal thresholds without major overnight hypoxaemia.69 participants completed a physiology screening night with an epiglottic catheter to quantify arousal threshold. 30 eligible patients (apnoea-hypopnoea index (AHI) 22±11 events·h-1) then completed standard in-laboratory polysomnography (baseline) and returned for two additional overnight sleep studies (nights 1 and 30) after receiving either nightly zopiclone (7.5 mg) or placebo during a 1-month, double-blind, randomised, parallel trial (ANZCTR identifier ANZCTRN12613001106729).The change in AHI from baseline to night 30 was not different between zopiclone versus placebo groups (-5.9±10.2 versus -2.4±5.5 events·h-1; p=0.24). Similarly, hypoxaemia, next-day sleepiness and driving simulator performance were not different.1 month of zopiclone does not worsen OSA severity, sleepiness or alertness in selected patients without major overnight hypoxaemia. As the first study to assess the effect of a hypnotic on OSA severity and sleepiness beyond single-night studies, these findings provide important safety data and insight into OSA pathophysiology.


获取全文 10.1183/13993003.00149-2018